Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ): Protein succinate iron oral solution receives drug registration certificate.

Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ) announced that the company recently received the "Drug Registration Certificate" for Protein Succinic Acid Iron Oral Solution issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). Protein succinic acid iron oral solution is used for absolute and relative iron-deficiency anemia caused by insufficient iron intake or absorption disorders, acute or chronic blood loss, infections, pregnancy, lactation, and other conditions. The approval of this product further enriches the company's product line and helps enhance the market competitiveness of the company's products. Due to the high technology, high risk, and high added value characteristics of pharmaceutical products, after obtaining approval, product sales may be affected by factors such as industry policy changes, tender procurement, market environment changes, and uncertainties.